This is a working overview of peptide backbone, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-07. Anything still debated is marked as such rather than presented as settled.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
In historical fungarium material, contamination can be especially severe because specimens were often stored in close contact on paper sheets or in herbarium packets, increasing the likelihood of cross-contamination, while universal fungal barcode primers may amplify contaminant fungi alongside the target specimen. High-throughput sequencing is better suited to such degraded material. In 2012, researchers reported successful ITS sequencing from a lichen herbarium specimen collected in 1859, then the oldest sequenced fungal herbarium sample. A 2025 study showed that historical lichen specimens, including type material, could be used for whole genome sequencing, allowing genome-wide analysis of both the fungal and algal symbionts. High-throughput sequencing can also recover barcode data from very small amounts of historical material, reducing the need for destructive sampling of valuable specimens while allowing taxonomic re-evaluation of long-preserved collections. A modified metabarcoding approach using nested, barcoded primers has enabled the cost-effective sequencing of hundreds of specimens simultaneously. In one study, this approach produced ITS sequences for 762 out of 766 macrofungal specimens, with taxonomic identities derived from the sequence data achieving over 90 percent accuracy. Such methods have allowed previously unidentified or misidentified specimens to be recognized under newer taxonomic concepts.
Original documents, data, and records (e.g., hospital records, clinical and office charts, laboratory notes, memoranda, subjects' diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate and complete, microfiches, photographic negatives, microfilm or magnetic media, x-rays, subject files, and records kept at the pharmacy, at the laboratories, and at medico-technical departments involved in the clinical trial). (ICH E6) Sponsor
On March 24, 2021, Schmitt announced his candidacy for the United States Senate to succeed incumbent Republican Roy Blunt. His candidacy was backed by Missouri mega-donor Rex Sinquefield. In the speech announcing his candidacy, Schmitt tied himself to Donald Trump and railed against "the radical left". He pledged to vote against Mitch McConnell as party leader in the Senate. Schmitt made his legal challenges to the Biden administration a major theme of his U.S. Senate campaign. The day before the primary, Trump released a statement endorsing "ERIC". Schmitt was joined in the Republican primary by two other candidates with that name, former governor Eric Greitens and lesser-known candidate Eric McElroy. Trump did not indicate which candidate or candidates he was endorsing, and declined to clarify. Politico reported it as an endorsement of both Greitens and Schmitt, as Trump had apparently expressed indecision about which of the two to back before a dual endorsement was suggested; he separately contacted both to pledge his support, and each subsequently claimed the endorsement as his. Schmitt won the Republican primary on August 2, 2022, with 45.6% of the vote. He won the general election with 55.4%, defeating Democratic nominee Trudy Busch Valentine by a margin of 13.2%.
=== Other characters === Nazuna (薺, Nazuna) Voiced by: Nao Toyama (Japanese); Sarah Wiedenheft (English) A little girl Hinagiku and Sakura meet while climbing Ryugu Peak. Her dramatic story prompts Hinagiku to perform the ritual of the Spring Manifestation. The little girl thus becomes the first witness of the return of Spring.
== Reception == Cry of Fear has received generally positive reviews, with reviewers praising its overall atmosphere and unique setting. Reviewers praised the game's story, atmosphere, tension, enemy designs, and inventory management, while some criticism was levied at the game's platforming segments and occasional crashes and bugs. Eric Sapp of IGN called the game "terrifying" and praised the addition of an inventory system with limited space similar to Resident Evil series for the decision making aspect. Antony Wright of SUPERJUMP named Cry of Fear "arguably the most disturbing and depraved horror title that I've ever played through" while also commending the game for sympathetically handling mature topics. Dennis Moiseyev and Destry Stutesman of The Gamer positively compared Cry of Fear to the Silent Hill series through its use of nightmare sequences, while employing a first-person perspective. Luke Plunkett of Kotaku opined that while the old engine made the game "a little janky" at times, the graphics and music in Cry of Fear were "genuinely tense". A review on Jeuxvideo.com praised the innovations to the GoldSrc engine, calling the improved the graphics and lighting in Cry of Fear unrecognized to Half-Life. Although acknowledging the technical limitations of an outdated engine, the music and "gloomy atmosphere" were also applauded by Jeuxvideo.com, stating the game proves "that a graphics engine, no matter how old it may be, can do some very beautiful things if it is used well".
Sources: en.wikipedia.org
Caitlin Thomas died in 1994 and was buried alongside her husband's grave. Thomas's father, "DJ", died on 16 December 1952 and his mother Florence in August 1958. Thomas's elder son, Llewelyn, died in 2000, his daughter, Aeronwy in 2009, and his younger son, Colm, in 2012.
In a joint statement on 13 January 2026, the prime ministers of Greenland and Denmark said that Greenland was facing an "unacceptable pressure" campaign and a "geopolitical crisis" caused by the US. They said that Greenland is not for sale under any circumstances. Frederiksen said, "our message is clear: Greenland is not for sale" and "you can't buy another people". Nielsen emphasised that talk about buying another people shows a lack of respect, and that Greenland does not want to be owned nor governed by the US. Greenlandic politicians have welcomed a NATO mission in Greenland to protect the island following Trump's threats.
== Plot == Maui Mallard is a "medium-boiled" detective visiting a tropical island when the mysterious Shabuhm Shabuhm idol goes missing. Shabuhm Shabuhm is considered the island's native guardian spirit, and unless the idol is recovered, the whole island will explode. Maui is put on the case, and his investigations lead him through a creepy mansion to ancient ninja training grounds -where he gains the ability to change into Cold Shadow- and a native village, where Maui is thrown into a volcano as a sacrifice to the native gods. Maui survives the volcano, and the islanders put him through the "test of duckhood", which Maui passes, gaining the natives' trust. The natives tell Maui that the only one who knows the location of Shabuhm Shabuhm has long since died, and Maui goes to recover his remains from the bottom of the sea before going through the land of the dead to escort his soul into rest. Ultimately, the location of Shabuhm Shabuhm is revealed, and Maui goes head-to-head with the witch doctor at his Mojo Stronghold over the idol. Maui is triumphant, and as a sign of their gratitude, the islanders name their island after their hero, despite their misgivings that the name "Mallard" has little potential for attracting tourists.
ERAP1 belongs to the oxytocinase subfamily of the M1-family of zinc metalloproteases. It is composed of four structural domains. Domain I (residues 1–254) consists of an eight-stranded ß-sheet and provides binding sites for the N-terminus of substrates. It fits against the catalytic domain II and engages with domain IV through an elongated loop. Domain II (residues 255–529) is the thermolysin-like catalytic domain, composed by an alpha-helix and a five stranded beta sheet. This sheet comprises the specific for exopeptidases GAMEN motif which creates one part of the substrate binding-cleft. The catalytic Zn atom is coordinated by the residues His353, His357 and Glu386, found in the zinc-binding motif (H-E-X-X-H-X18-E) on the helix 6a. Domain III (residues 530–614) is composed by two beta-sheets forming a beta sandwich and acts as a linker between domains II and IV. Finally, domain IV (615–941) consists mainly of a-helices and exhibits a bowl-shaped form. At the closed (active) state, it juxtaposes with domain II forming a large internal cavity, which holds the C-term substrate binding site (Figure 2A). It is the most variable domain among this family of aminopeptidases.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.